Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... June 29, 2021 Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... June 26, 2019 Load more HOT NEWS Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... Can the New “Omics” on the Block Find Liver Cancer in...
